Survo
A 29-residue acylated synthetic peptide characterized in cell-based receptor-pharmacology and structural research.
Quick answers
What is Survo?
Survo is a 29-residue acylated synthetic peptide characterized in cell-based receptor-pharmacology and structural research. It is a synthetic peptide (acylated, 29 residues) with a molecular weight of ~4,232 g/mol and the formula C192H289N47O61.
How much published research cites Survo?
The Luvaminos Survo record cites 20 published references, dated 2022 to 2026. Each is listed on this page with a link to its source.
Does Luvaminos test Survo, and where is the certificate?
Luvaminos does not currently stock Survo. Every peptide lot Luvaminos sells is tested by Freedom Diagnostics Testing, PLLC, an independent laboratory, and its certificate is published at luvaminos.com/coa under the lot number printed on the vial.
What modifications does Survo carry?
Survo: Position 2 substituted with Ac4c (1-aminocyclobutane-1-carboxylic acid).
How is Survo powder stored?
Sealed Survo powder: -20°C with desiccant; avoid repeated freeze–thaw; lyophilized form is stable for extended periods when properly stored and sealed.
Molecular Profile
- Type
- Synthetic peptide (acylated, 29 residues)
- Molecular formula
- C192H289N47O61
- Molecular weight
- ~4,232 g/mol
- CAS number
- 2805997-46-8
- Amino acids
- 29
- Fatty acid chain
- C18 diacid
- Modification
- Position 2 substituted with Ac4c (1-aminocyclobutane-1-carboxylic acid); Lys-24 side chain acylated with an 18-carbon fatty diacid for albumin binding and extended half-life.
Mechanism & Target Class
Survo is a 29-residue synthetic peptide that engages class B G protein–coupled receptors. Its backbone carries substitutions including a non-natural amino acid at position 2 (Ac4c, 1-aminocyclobutane-1-carboxylic acid). An 18-carbon dicarboxylic acid covalently attached to the Lys-24 side chain confers reversible albumin binding, extending plasma half-life. These structural features — non-coded residues and fatty-acid acylation — are shared with other long-acting class B GPCR ligands studied in this research area.
Storage & Handling
- Lyophilized
- -20°C with desiccant; avoid repeated freeze–thaw; lyophilized form is stable for extended periods when properly stored and sealed.
- Handling
- sterile conditions minimize oxidative and microbial exposure.
Primary Database
References (20)
Reviews
1Winther JB, Holst JJ. (2024). Diabetes Obes Metab
- 2
Novikoff A, Müller TD. (2023). Peptides
- 3
Kajani S, Laker RC, Ratkova E, et al. (2024). Physiol Rev
- 4
Alfaris N, Waldrop S, Johnson V, et al. (2024). EClinicalMedicine
- 5
Wen J, How-Volkman C, Truong A, et al. (2024). Cureus
- 6
Yao Z, Wang C, Zhu Q, et al. (2023). Peptides
- 7
Li M, Hu J, Chin YH, et al. (2025). Front Endocrinol
- 8
Mantovani A, Morandin R, Fiorio V, et al. (2025). Liver Int
- 9
Stachteas P, Nasoufidou A, Karakasis P, et al. (2025). Rev Cardiovasc Med
- 10
Zafer M, Tavaglione F, Romero-Gómez M, et al. (2025). Aliment Pharmacol Ther
Primary research
11Le Roux CW, Steen O, Lucas KJ, et al. (2024). Lancet Diabetes Endocrinol
- 12
Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2024). N Engl J Med
- 13
Sanyal AJ, Mazo DF, Younes R, et al. (2024). J Hepatol
- 14
Thomas L, Martel E, Rist W, et al. (2024). Diabetes Obes Metab
- 15
Romero-Gómez M, Lawitz E, Shankar RR, et al. (2023). J Hepatol
- 16
Zimmermann T, Thomas L, Baader-Pagler T, et al. (2022). Mol Metab
- 17
Li Y, Zhou Q, Dai A, et al. (2023). Proc Natl Acad Sci USA
- 18
Corbin KD, Carnero EA, Allerton TD, et al. (2023). Obesity (Silver Spring)
- 19
Shankar SS, Daniels SJ, Robertson D, et al. (2024). Clin Gastroenterol Hepatol
- 20
Zimmermann T, Bleymehl K, Haebel P, et al. (2026). Mol Metab
Related compounds